AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Novel Ligands for HIV-1 Protease Inhibitors
Summary
Purdue University researchers have designed and synthesized a novel class of HIV-1 protease inhibitors, which show potency 10x greater than that of Darunavir, an FDA-approved inhibitor developed by the same researchers. A number of these inhibitors are very potent against multidrug-resistant HIV-1 variants and could lead to additional drugs used in HIV/AIDS treatment.
Technology Benefits
HIV therapeutic with 10-fold potency increase over current standardEffective for the treatment of multidrug-resistant strains of HIV
Technology Application
Medical/HealthcarePharmaceuticalsHIV/AIDS TreatmentDrug Development
Detailed Technology Description
Arun GhoshGhosh GroupPurdue Chemistry
Countries
United States
Application No.
8,563,597
Country/Region
USA
For more information, please click Here
